Detalles de la búsqueda
1.
Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
Blood
; 140(10): 1167-1181, 2022 09 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35853161
2.
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
J Allergy Clin Immunol
; 146(2): 356-366.e4, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32437738
3.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
N Engl J Med
; 376(10): 917-927, 2017 03 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28273028
4.
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
Blood
; 125(18): 2771-8, 2015 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25766724
5.
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Blood
; 123(9): 1353-60, 2014 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24335106
6.
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Haematologica
; 99(7): 1204-11, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24532039
7.
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.
Eur J Nucl Med Mol Imaging
; 41(5): 867-77, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24435772
8.
Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
Cancer Chemother Pharmacol
; 93(5): 439-453, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38270613
9.
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Haematol
; 11(1): e38-e50, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38065203
10.
Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.
J Surg Oncol
; 107(2): 173-9, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22674435
11.
MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production.
Mol Cancer Res
; 21(8): 849-864, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37071397
12.
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients.
Blood
; 113(10): 2265-74, 2009 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-19131554
13.
A review of the current evidence for maintenance therapy in ovarian cancer.
Gynecol Oncol
; 115(2): 290-301, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19717182
14.
Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2-Arm, Crossover, Randomized, Open-Label Study in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 8(3): 385-394, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30059193
15.
Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
Cancer Chemother Pharmacol
; 2024 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38438807
16.
Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
J Cancer Res Clin Oncol
; 144(3): 499-507, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29327244
17.
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.
J Clin Oncol
; 20(9): 2353-9, 2002 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-11981007
18.
Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study.
Clin Cancer Res
; 10(4): 1299-305, 2004 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-14977828
19.
The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.
Cell Adh Migr
; 9(1-2): 14-21, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25562532
20.
Wilms tumor gene (WT1) expression as a panleukemic marker.
Int J Hematol
; 76(2): 103-9, 2002 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12215007